Hypercortisolism – Medxy AI

Impact of Hypercortisolism Severity on Outcomes in Adrenocortical Carcinoma with Cushing’s Syndrome

By MedXY 09/15/2026

This study reveals that the severity of hypercortisolism in adrenocortical carcinoma patients with Cushing’s syndrome correlates with higher metastatic risk and worse survival outcomes, highlighting its role as a marker of tumor aggressiveness.

Diabetes & Endocrinology Internal Medicine news

Cushing’s Syndrome in the Elderly: Diagnostic and Therapeutic Nuances in an Aging Population

By MedXY 09/08/2026

Cushing’s syndrome in older adults requires a tailored diagnostic approach and individualized management that prioritizes functional status and quality of life over chronological age, accounting for atypical presentations and comorbidities.

Diabetes & Endocrinology news

Efficacy and Safety of Osilodrostat in Adrenal Cushing Syndrome: Insights from an International Real-World Study

By MedXY 07/16/2026

This international real-world study demonstrates that osilodrostat effectively controls hypercortisolism in adrenal Cushing syndrome, with improved blood pressure and body weight, and highlights better response in patients previously treated with other steroidogenesis inhibitors.